Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis
Tiago Torres, L. Puig
American Journal of Clinical Dermatology (2017) Vol. 19, Iss. 1, pp. 23-32
Closed Access | Times Cited: 81

Showing 26-50 of 81 citing articles:

The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast
I. Arias de la Rosa, Maria Dolores López‐Montilla, Cristóbal Román-Rodríguez, et al.
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 676-693
Open Access | Times Cited: 17
DNA methylation patterns in CD4+ T-cells separate psoriasis patients from healthy controls, and skin psoriasis from psoriatic arthritis
Valentina Natoli, Amandine Charras, Sigrun R. Hofmann, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Oral roflumilast for psoriasis: a real-world 24-week prospective cohort study
Ana Maria Lé, Orhan Yilmaz, Martim Luz, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access
Rituximab, Apremilast, and Upadacitinib as Selected Biosimilar and Targeted Synthetic Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action: Their Current Use in Slowing Down the Progression of Disease
Piotr Kawczak, Igor Feszak, Tomasz Bączek
Journal of Clinical Medicine (2025) Vol. 14, Iss. 8, pp. 2605-2605
Open Access
Discovery of wedelolactone from Eclipta Prostrata (L.) Linn. as a natural PDE4 inhibitor with potent anti-psoriasis effects
Lingyu Wu, Yingying Wu, Shengchao Yang, et al.
Acta Materia Medica (2025) Vol. 4, Iss. 3
Open Access
Tofacitinib: A New Oral Therapy for Psoriasis
Alexandra Azevedo, Tiago Torres
Clinical Drug Investigation (2017) Vol. 38, Iss. 2, pp. 101-112
Closed Access | Times Cited: 31
Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post‐marketing surveillance study
Mamitaro Ohtsuki, Yukari Okubo, Hidehisa Saeki, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 7, pp. 950-963
Open Access | Times Cited: 3
New and emerging oral therapies for psoriasis
Orhan Yılmaz, João Pedro Pinto, Tiago Torres
Drugs in Context (2024) Vol. 13, pp. 1-24
Open Access | Times Cited: 3
Apremilast Improves Endothelial Glycocalyx Integrity, Vascular and Left Ventricular Myocardial Function in Psoriasis
Ignatios Ikonomidis, George Pavlidis, Nikolaos P.E. Kadoglou, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 2, pp. 172-172
Open Access | Times Cited: 13
Topical roflumilast for the treatment of psoriasis
Anastasia Drakos, Ronald Vender, Tiago Torres
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 9, pp. 1053-1062
Closed Access | Times Cited: 7
Psoriasis asociada al VIH
N. Queirós, Tiago Torres
Actas Dermo-Sifiliográficas (2018) Vol. 109, Iss. 4, pp. 303-311
Closed Access | Times Cited: 23
Apremilast for psoriasis treatment
J.M. Carrascosa, Elena Del-Alcazar
Giornale Italiano di Dermatologia e Venereologia (2020) Vol. 155, Iss. 4
Closed Access | Times Cited: 19
Apremilast for immune checkpoint inhibitor-induced psoriasis: A case series
Ander Mayor Ibarguren, Enrique Espinosa, Peiteado Lopez Diana, et al.
JAAD Case Reports (2021) Vol. 11, pp. 84-89
Open Access | Times Cited: 17
Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report
Maria Anna Siciliano, Stefano Dastoli, Maria D’Apolito, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 18
Chiral Separation of Apremilast by Capillary Electrophoresis Using Succinyl-β-Cyclodextrin—Reversal of Enantiomer Elution Order by Cationic Capillary Coating
Zoltán‐István Szabó, Beáta-Mária Benkő, Ágnes Bartalis-Fábián, et al.
Molecules (2023) Vol. 28, Iss. 8, pp. 3310-3310
Open Access | Times Cited: 6
Targeted Therapy for Pediatric Psoriasis
Miguel Nogueira, Amy S. Paller, Tiago Torres
Pediatric Drugs (2021) Vol. 23, Iss. 3, pp. 203-212
Closed Access | Times Cited: 14
Break on through: The role of innate immunity and barrier defence in atopic dermatitis and psoriasis
Heike C. Hawerkamp, Caoimhe Fahy, Padraic G. Fallon, et al.
Skin Health and Disease (2022) Vol. 2, Iss. 2
Open Access | Times Cited: 10
HIV-associated psoriasis
N. Queirós, Tiago Torres
Actas Dermo-Sifiliográficas (2018) Vol. 109, Iss. 4, pp. 303-311
Open Access | Times Cited: 15
Managing psoriatic arthritis in different clinical scenarios
Rubén Queiró, Marta Loredo, Ignacio Braña, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 12, pp. 1469-1484
Closed Access | Times Cited: 4
Pharmacokinetics and Bioequivalence of Apremilast Tablets in Chinese Healthy Subjects Under Fasting and Postprandial States
Wanjun Bai, Xue Sun, Bo Qiu, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 2273-2285
Open Access | Times Cited: 1
Apremilast Use in a Case of Cicatricial Ectropion Secondary to Severe Lamellar Ichthyosis
Jean-Paul J. Abboud, Alex Whittington, Masih Ahmed, et al.
Ophthalmic Plastic and Reconstructive Surgery (2018) Vol. 34, Iss. 3, pp. e76-e77
Closed Access | Times Cited: 11
Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections
Valeria Manfreda, Maria Esposito, Elena Campione, et al.
Postgraduate Medicine (2019) Vol. 131, Iss. 3, pp. 239-240
Closed Access | Times Cited: 10
Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art
Francesco Caso, Luca Navarini, Piero Ruscitti, et al.
Expert Opinion on Pharmacotherapy (2020) Vol. 21, Iss. 7, pp. 785-796
Closed Access | Times Cited: 10
Psoriatic arthritis and COVID ‐19 pandemic: Consequences in medical treatment?
Uwe Wollina, Massimo Fioranelli, Mohamad Goldust, et al.
Dermatologic Therapy (2020) Vol. 33, Iss. 5
Open Access | Times Cited: 10
Immunomodulatory drugs alone and adjuvant to surgery for hidradenitis suppurativa/acne inversa—A narrative review
Uwe Wollina, Piotr Brzeziński, André Koch, et al.
Dermatologic Therapy (2020) Vol. 33, Iss. 6
Open Access | Times Cited: 10

Scroll to top